Volume 50, Issue 8 pp. 739-747
ORIGINAL ARTICLE

Clinicopathologic and genetic characterization of invasive melanoma with BRAF V600K mutation: A study of 16 cases

Keisuke Goto MD

Corresponding Author

Keisuke Goto MD

Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan

Department of Dermatology, Hyogo Cancer Center, Akashi, Japan

Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan

Department of Pathology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan

Department of Pathology, Itabashi Central Clinical Laboratory, Tokyo, Japan

Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan

Department of Diagnostic Pathology, Chutoen General Medical Center, Kakegawa, Japan

Department of Clinical Laboratory and Diagnostic Pathology, Osaka National Hospital, Osaka, Japan

Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan

Correspondence

Keisuke Goto, Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, 1007 Shimonagakubo, Nagaizumi, Sunto, Shizuoka 411-8777, Japan.

Email: [email protected]

Search for more papers by this author
Shusuke Yoshikawa MD

Shusuke Yoshikawa MD

Department of Dermatology, Shizuoka Cancer Center Hospital, Sunto, Japan

Search for more papers by this author
Toshihiro Takai MD

Toshihiro Takai MD

Department of Dermatology, Hyogo Cancer Center, Akashi, Japan

Search for more papers by this author
Kota Tachibana MD, PhD

Kota Tachibana MD, PhD

Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Melanoma Center, Okayama University Hospital, Okayama, Japan

Search for more papers by this author
Keiichiro Honma MD, PhD

Keiichiro Honma MD, PhD

Department of Diagnostic Pathology and Cytology, Osaka International Cancer Institute, Osaka, Japan

Search for more papers by this author
Taiki Isei MD, PhD

Taiki Isei MD, PhD

Department of Dermatologic Oncology, Osaka International Cancer Institute, Osaka, Japan

Search for more papers by this author
Yoji Kukita PhD

Yoji Kukita PhD

Laboratory of Genomic Pathology, Research Center, Osaka International Cancer Institute, Osaka, Japan

Search for more papers by this author
Takuma Oishi MD, PhD

Takuma Oishi MD, PhD

Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan

Search for more papers by this author
First published: 25 May 2023

Abstract

Background

The clinicopathologic and genetic features of cutaneous melanoma with a BRAF V600K mutation are not well-known. We aimed to evaluate these characteristics in comparison with those associated with BRAF V600E.

Methods

Real-time polymerase chain reaction (PCR) and/or the MassARRAY® system were used to detect BRAF V600K in 16 invasive melanomas and confirm BRAF V600E in another 60 cases. Immunohistochemistry and panel next-generation sequencing were used to evaluate protein expression and tumor mutation burden, respectively.

Results

The median age of melanoma patients harboring the BRAF V600K mutation (72.5 years) was higher than those with the BRAF V600E (58.5 years). The two groups also differed in sex (13/16 [81.3%] male in the V600K group vs. 23/60 [38.3%] in V600E) and in the frequency of scalp involvement (8/16 [50.0%] in V600K vs. 1/60 [1.6%] in V600E). The clinical appearance was similar to a superficial spreading melanoma. Histopathologically, non-nested lentiginous intraepidermal spread and subtle solar elastosis were observed. One patient (1/13, 7.7%) had a pre-existing intradermal nevus. Diffuse PRAME immunoexpression was seen in only one (14.3%) of seven tested cases. Loss of p16 expression was observed in all 12 cases (100%) analyzed. The tumor mutation burden was 8 and 6 mutations/Mb in the two tested cases.

Conclusions

Melanoma carrying the BRAF V600K mutation showed the predominance on the scalp of elderly men, lentiginous intraepidermal growth, subtle solar elastosis, possible existence of intradermal nevus component, frequent loss of p16 immunoexpression, limited immunoreactivity for PRAME, and intermediate tumor mutation burden.

CONFLICT OF INTEREST STATEMENT

The authors disclose that they have no significant relationships with or financial interests in any commercial companies pertaining to this study.

DATA AVAILABILITY STATEMENT

The datasets generated and analyzed during the present study are available from the corresponding author upon reasonable request and IRB approval, but are not publicly available due to privacy or ethical restrictions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.